These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 34278290)

  • 21. Rapidly progressive IgA nephropathy with membranoproliferative glomerulonephritis-like lesions in an elderly man following the third dose of an mRNA COVID-19 vaccine: a case report.
    Morimoto N; Mori T; Shioji S; Taguchi T; Watanabe H; Sakai K; Mori K; Yamamura A; Hanioka A; Akagi Y; Fujiki T; Mandai S; Mori Y; Ando F; Susa K; Iimori S; Naito S; Sohara E; Ohashi K; Uchida S
    BMC Nephrol; 2023 Apr; 24(1):108. PubMed ID: 37095451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2-Specific Immune Responses in Vaccination and Infection during the Pandemic in 2020-2022.
    Inoue W; Kimura Y; Okamoto S; Nogimori T; Sakaguchi-Mikami A; Yamamoto T; Tsunetsugu-Yokota Y
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Zhu F; Zhuang C; Chu K; Zhang L; Zhao H; Huang S; Su Y; Lin H; Yang C; Jiang H; Zang X; Liu D; Pan H; Hu Y; Liu X; Chen Q; Song Q; Quan J; Huang Z; Zhong G; Chen J; Han J; Sun H; Cui L; Li J; Chen Y; Zhang T; Ye X; Li C; Wu T; Zhang J; Xia NS
    Lancet Respir Med; 2022 Aug; 10(8):749-760. PubMed ID: 35644168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic and mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection.
    Sheikh-Mohamed S; Isho B; Chao GYC; Zuo M; Cohen C; Lustig Y; Nahass GR; Salomon-Shulman RE; Blacker G; Fazel-Zarandi M; Rathod B; Colwill K; Jamal A; Li Z; de Launay KQ; Takaoka A; Garnham-Takaoka J; Patel A; Fahim C; Paterson A; Li AX; Haq N; Barati S; Gilbert L; Green K; Mozafarihashjin M; Samaan P; Budylowski P; Siqueira WL; Mubareka S; Ostrowski M; Rini JM; Rojas OL; Weissman IL; Tal MC; McGeer A; Regev-Yochay G; Straus S; Gingras AC; Gommerman JL
    Mucosal Immunol; 2022 May; 15(5):799-808. PubMed ID: 35468942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit.
    Hsieh HC; Chen CC; Chou PH; Liu WC; Wu SC
    Antiviral Res; 2023 Dec; 220():105752. PubMed ID: 37949318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
    Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
    Front Immunol; 2022; 13():816389. PubMed ID: 35464418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative longitudinal variation of total IgG and IgA anti-SARS-CoV-2 antibodies in recipients of BNT162b2 vaccination.
    Lippi G; Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi G
    Adv Lab Med; 2022 Mar; 3(1):39-50. PubMed ID: 37359438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Human Milk Antibody Induction, Persistence, and Neutralizing Capacity With SARS-CoV-2 Infection vs mRNA Vaccination.
    Young BE; Seppo AE; Diaz N; Rosen-Carole C; Nowak-Wegrzyn A; Cruz Vasquez JM; Ferri-Huerta R; Nguyen-Contant P; Fitzgerald T; Sangster MY; Topham DJ; Järvinen KM
    JAMA Pediatr; 2022 Feb; 176(2):159-168. PubMed ID: 34757387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
    Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
    Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response.
    Takamatsu Y; Omata K; Shimizu Y; Kinoshita-Iwamoto N; Terada M; Suzuki T; Morioka S; Uemura Y; Ohmagari N; Maeda K; Mitsuya H
    Microbiol Spectr; 2022 Dec; 10(6):e0271622. PubMed ID: 36219096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Potential Role of an Aberrant Mucosal Immune Response to SARS-CoV-2 in the Pathogenesis of IgA Nephropathy.
    Zhang Z; Zhang G; Guo M; Tao W; Liu X; Wei H; Jin T; Zhang Y; Zhu S
    Pathogens; 2021 Jul; 10(7):. PubMed ID: 34358031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
    Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
    Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
    Stellini R; Gianello R; Gomarasca W
    Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).
    Ruetalo N; Flehmig B; Schindler M; Pridzun L; Haage A; Reichenbächer M; Kirchner T; Kirchner T; Klingel K; Ranke MB; Normann A
    Viruses; 2021 Nov; 13(12):. PubMed ID: 34960605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster.
    Nolan TM; Deliyannis G; Griffith M; Braat S; Allen LF; Audsley J; Chung AW; Ciula M; Gherardin NA; Giles ML; Gordon TP; Grimley SL; Horng L; Jackson DC; Juno JA; Kedzierska K; Kent SJ; Lewin SR; Littlejohn M; McQuilten HA; Mordant FL; Nguyen THO; Soo VP; Price B; Purcell DFJ; Ramanathan P; Redmond SJ; Rockman S; Ruan Z; Sasadeusz J; Simpson JA; Subbarao K; Fabb SA; Payne TJ; Takanashi A; Tan CW; Torresi J; Wang JJ; Wang LF; Al-Wassiti H; Wong CY; Zaloumis S; Pouton CW; Godfrey DI
    EBioMedicine; 2023 Dec; 98():104878. PubMed ID: 38016322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.
    Lee KS; Rader NA; Miller-Stump OA; Cooper M; Wong TY; Shahrier Amin M; Barbier M; Bevere JR; Ernst RK; Heath Damron F
    Vaccine; 2023 Jul; 41(34):5003-5017. PubMed ID: 37407405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 9-Month observational Dia-Vacc study of vaccine type influence on SARS-CoV-2 immunity in dialysis and kidney transplant patients.
    Stumpf J; Anders L; Siepmann T; Schwöbel J; Karger C; Lindner T; Faulhaber-Walter R; Langer T; Escher K; Anding-Rost K; Seidel H; Hüther J; Pistrosch F; Martin H; Schewe J; Stehr T; Meistring F; Paliege A; Schneider D; Bast I; Steglich A; Gembardt F; Kessel F; Kröger H; Arndt P; Sradnick J; Frank K; Skrzypczyk S; Anft M; Klimova A; Mauer R; Roeder I; Tonn T; Babel N; Hugo C
    Vaccine; 2024 Jan; 42(2):120-128. PubMed ID: 38114410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insufficient anti-spike RBD IgA responses after triple vaccination with intramuscular mRNA BNT162b2 vaccine against SARS-CoV-2.
    Yoshimura M; Sakamoto A; Ozuru R; Kurihara Y; Itoh R; Ishii K; Shimizu A; Chou B; Sechi Y; Fujikane A; Nabeshima S; Hiromatsu K
    Heliyon; 2024 Jan; 10(1):e23595. PubMed ID: 38187240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.